INTRODUCTION: In vivo deastatination of (211)At-labeled biomolecules can severely limit their use in endoradiotherapy. Our studies have shown that the use of closo-decaborate(2-) moiety for (211)At-labeling of biomolecules provides high in vivo stability towards deastatination. However, data from those studies have also been suggestive that some astatinated closo-decaborate(2-) catabolites may be retained in tissues. In this study, we investigated the in vivo distributions of several structurally simple closo-decaborate(2-) derivatives to gain information on the effects of functional groups if catabolites are released into the blood system from the carrier biomolecule. METHODS: Thirteen closo-decaborate(2-) derivatives were synthesized and radioiodinated for evaluation. Tissue concentrations of the radioiodinated compounds were obtained in groups of five mice at 1 and 4 h postinjection (pi). Dual-label ((125)I and (131)I) experiments permitted evaluation of two compounds in each set of mice. RESULTS: All of the target compounds were readily synthesized. Radioiodination reactions were conducted with chloramine-T and Na[(125/131)I]I in water to give high yields (75-96%) of the desired compounds. Biodistribution data at 1 and 4 h pi (representing catabolites released into the blood system) showed small differences in tissue concentrations for some compounds, but large differences for others. The results indicate that formal (overall) charge on the compounds could not be used as a predictor of tissue localization or retention. However, derivatives containing carboxylate groups generally had lower tissue concentrations. Acid cleavable hydrazone functionalities appeared to be the best candidates for further study. CONCLUSIONS: Further studies incorporating hydrazone functionalities into pendant groups for biomolecule radiohalogenation are warranted. (c) 2010 Elsevier Inc. All rights reserved.
INTRODUCTION: In vivo deastatination of (211)At-labeled biomolecules can severely limit their use in endoradiotherapy. Our studies have shown that the use of closo-decaborate(2-) moiety for (211)At-labeling of biomolecules provides high in vivo stability towards deastatination. However, data from those studies have also been suggestive that some astatinated closo-decaborate(2-) catabolites may be retained in tissues. In this study, we investigated the in vivo distributions of several structurally simple closo-decaborate(2-) derivatives to gain information on the effects of functional groups if catabolites are released into the blood system from the carrier biomolecule. METHODS: Thirteen closo-decaborate(2-) derivatives were synthesized and radioiodinated for evaluation. Tissue concentrations of the radioiodinated compounds were obtained in groups of five mice at 1 and 4 h postinjection (pi). Dual-label ((125)I and (131)I) experiments permitted evaluation of two compounds in each set of mice. RESULTS: All of the target compounds were readily synthesized. Radioiodination reactions were conducted with chloramine-T and Na[(125/131)I]I in water to give high yields (75-96%) of the desired compounds. Biodistribution data at 1 and 4 h pi (representing catabolites released into the blood system) showed small differences in tissue concentrations for some compounds, but large differences for others. The results indicate that formal (overall) charge on the compounds could not be used as a predictor of tissue localization or retention. However, derivatives containing carboxylate groups generally had lower tissue concentrations. Acid cleavable hydrazone functionalities appeared to be the best candidates for further study. CONCLUSIONS: Further studies incorporating hydrazone functionalities into pendant groups for biomolecule radiohalogenation are warranted. (c) 2010 Elsevier Inc. All rights reserved.
Authors: D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Brian B Kegley; Janna Quinn; Robert L Vessella Journal: Bioconjug Chem Date: 2004 May-Jun Impact factor: 4.774
Authors: D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Robert L Vessella; Timothy J Wedge; M Frederick Hawthorne Journal: Bioconjug Chem Date: 2007-06-21 Impact factor: 4.774
Authors: O W Press; D Shan; J Howell-Clark; J Eary; F R Appelbaum; D Matthews; D J King; A M Haines; P Hamann; L Hinman; D Shochat; I D Bernstein Journal: Cancer Res Date: 1996-05-01 Impact factor: 12.701
Authors: D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella Journal: Bioconjug Chem Date: 2011-05-05 Impact factor: 4.774
Authors: Yawen Li; Donald K Hamlin; Ming-Kuan Chyan; Roger Wong; Eric F Dorman; Robert C Emery; Douglas R Woodle; Ronald L Manger; Margaret Nartea; Aimee L Kenoyer; Johnnie J Orozco; Damian J Green; Oliver W Press; Rainer Storb; Brenda M Sandmaier; D Scott Wilbur Journal: PLoS One Date: 2018-10-18 Impact factor: 3.240
Authors: Alexey V Nelyubin; Nikita A Selivanov; Alexander Yu Bykov; Ilya N Klyukin; Alexander S Novikov; Andrey P Zhdanov; Natalia Yu Karpechenko; Mikhail S Grigoriev; Konstantin Yu Zhizhin; Nikolay T Kuznetsov Journal: Int J Mol Sci Date: 2021-12-13 Impact factor: 5.923